Segall Bryant & Hamill, LLC Neurocrine Biosciences Inc Transaction History
Segall Bryant & Hamill, LLC
- $6.35 Billion
- Q1 2025
A detailed history of Segall Bryant & Hamill, LLC transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Segall Bryant & Hamill, LLC holds 53,103 shares of NBIX stock, worth $6.51 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
53,103
Previous 46,870
13.3%
Holding current value
$6.51 Million
Previous $6.4 Million
8.19%
% of portfolio
0.09%
Previous 0.09%
Shares
5 transactions
Others Institutions Holding NBIX
# of Institutions
650Shares Held
97.2MCall Options Held
749KPut Options Held
553K-
Black Rock Inc. New York, NY14.2MShares$1.74 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.94MShares$1.22 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA5.53MShares$679 Million0.37% of portfolio
-
State Street Corp Boston, MA4.86MShares$596 Million0.02% of portfolio
-
Jpmorgan Chase & CO New York, NY2.67MShares$328 Million0.02% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.7B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...